Jiangsu, China

Xiaohan Geng

This inventor holds 1 USPTO granted patent. Top assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing Gear Pharma & Tech Co., Ltd.. Active years: 2022.


% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Xiaohan Geng

Introduction: Xiaohan Geng is an accomplished inventor based in Jiangsu, China, known for his significant contributions to pharmaceutical innovation. With a focus on developing novel compounds, Geng has made strides in the field of medicine through his patented inventions.

Latest Patents: Xiaohan Geng holds a notable patent for a sulfonyl-substituted bicyclic compound that acts as a RORγ inhibitor. This compound demonstrates promising RORγ inhibitory activity and is anticipated to be effective in treating diseases mediated by the RORγ receptor in mammals.

Career Highlights: Throughout his career, Geng has worked with leading pharmaceutical companies including Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Nanjing Gear Pharma & Tech Co., Ltd. His expertise in drug development and innovation has positioned him as a key player in the industry.

Collaborations: In his professional journey, Geng has collaborated with talented individuals such as Xiaolong Wang and Anle Yang. Working alongside these professionals, he has contributed to advancing pharmaceutical research and developing innovative solutions.

Conclusion: Xiaohan Geng's work exemplifies the spirit of innovation within the pharmaceutical field. His dedication to creating effective treatments through innovative compounds signifies a promising future for addressing diseases related to the RORγ receptor. As he continues to build on his expertise and collaborations, Geng remains a notable figure in the world of inventions and patent development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…